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Abstract Aims/hypothesis: Plasma semicarbazide-sensi-
tive amine oxidase (SSAO) is elevated in patients with type
1 and type 2 diabetes and has been implicated in the patho-
physiology of diabetic late complications. The regulation of
SSAO production remains unknown. We studied correla-
tions between plasma SSAO activity and parameters asso-
ciated with diabetic late complications. Methods: Plasma
SSAO was measured in a well-characterised group of 287
patients with type 1 diabetes. Standard statistical methods
were used to investigate correlations with clinical param-
eters and components of the renin–angiotensin system.
Results: Overall, plasma SSAO was elevated, at 693±196
mU/l (mean±SD; normal controls 352±102 mU/l). Plasma
SSAO was higher in the group with late complications or
hypertension, and in patients treated with ACE-inhibitors.
In univariate analysis a significant positive correlation
(p<0.001, r=0.27) was found between plasma SSAO and
serum ACE activity in patients untreated with ACE in-
hibitors or angiotensin II receptor antagonists (n=221), but
plasma SSAO did not differ by ACE I/D genotype. Plasma
SSAO correlated positively with duration of diabetes,
HbA1c and plasma renin, and negatively with plasma an-
giotensinogen and body mass index. A multiple regression
analysis including these variables resulted in serum ACE
activity (p<0.001), ACE genotype (negatively, p<0.001)
andHbA1c (p=0.023) as explaining variables. Conclusions/
interpretation: Results suggest that a common factor is in-
volved in the regulation of both plasma SSAO and serum
ACE, which is different from the genetic determination of
ACE activity.
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Introduction
Semicarbazide-sensitive amine oxidase (SSAO) is an
enzyme widely present in nature. In man, a membrane-
bound form is abundantly present in vascular endothelial
and smooth muscle cells and in adipocytes, while a soluble
form circulates in plasma (for a recent review, see [1]).
SSAO appears to have multiple functions. As an enzyme
it can transform exogenous primary amines like allylamine
and benzylamine, and endogenous amines like methyl-
amine and aminoacetone, into the corresponding aldehydes,
at the same time generating hydrogen peroxide and am-
monia. These products are all (cyto)toxic. Furthermore, it
was recently discovered that vascular adhesion protein-1
(VAP-1), which is involved in the extravasation of leuco-
cytes, is identical to SSAO [2]. An increasing body of
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mainly experimental evidence links SSAO to vascular
damage, formation of AGE, linkage of proteins to form
insoluble products, atherosclerosis and oxidative stress
[1, 3–5]. On the other hand, SSAO is involved in the re-
cruitment of the glucose transporter GLUT4 to the cell
membrane through local formation of the signalling mol-
ecule hydrogen peroxide [6]. Thus, SSAO, together with a
suitable substrate, can mimic the action of insulin and in-
crease glucose uptake.
Plasma SSAO is probably derived from the membrane-
bound form [7–9] and its activity normally seems to be well
regulated within a relatively small range. It is not yet known
which factors are involved in the regulation. However,
circulating SSAO has been found to be elevated in type 1
and type 2 diabetes [10–13], in the former already at the
time of diagnosis. The mechanism behind the elevation of
plasma SSAO in diabetes is not known.
We hypothesised that by investigating correlations of
plasma SSAO activity with other factors involved in the
pathophysiology of diabetes and its late complications, we
might find clues about the regulatory mechanisms. One
such factor is the renin–angiotensin system (RAS). Al-
though some parameters of the RAS (renin and angiotensin
II) do not appear to be elevated in diabetes [14], some others
are. Thus, serum ACE activity is increased in patients with
diabetes aggravated by late complications, while the risk of
severe hypoglycaemia is related to elevated serum ACE
activity [15]. Serum ACE activity is, however, a highly
heritable trait, with a large part of interindividual variability
in ACE levels being due to genetic variation in the ACE
gene [16–20]. In this study we determined plasma SSAO
activities in a large group of well-characterised patients with
type 1 diabetes and investigated correlations with clinical
parameters, as well as with components of the renin–an-
giotensin system (renin, angiotensinogen, ACE activity and
genotype, angiotensin II receptor subtype 1 [AT1R] and
subtype 2 [AT2R] genotype).
Subjects and methods
A total of 287 consecutive adult patients were recruited
from the outpatient clinic at Hillerød Hospital, Denmark.
They had all had type 1 diabetes mellitus for more than 2
years and did not have significant comorbidity beside late
complications and hypertension, were not pregnant and not
on haemodialysis. The presence of late complications was
defined as existing retinopathy (untreated or laser-treated),
and/or nephropathy (micro-albuminuria, proteinuria, or
high serum creatinine), and/or neuropathy (senso-motor or
autonomic, symptomatic or asymptomatic), stroke, myo-
cardial infarction/angina or amputation as described pre-
viously [15]. The study was approved by the regional ethics
committee and written informed consent was obtained from
all patients.
Plasma SSAO activity was measured by a functional
assay using benzylamine as substrate [21]. Serum ACE
activity, HbA1c and ACE I/D, AT1R (AT1R 1166A>C) and
AT2R (AT2R 1675A>G) genotypes were determined as
previously reported [15, 22, 23]. Renin concentrations were
measured by radioimmunoassay of generated angiotensin I,
as was angiotensinogen in the presence of added excess of
renin [24].
Standard statistical methods for descriptive and com-
parative analysis as well as for single and multiple regres-
sion analysis were used, employing the SPSS software
package (version 10.0). In the backward stepwise multiple
regression model with SSAO as the dependent variable,
serumACEactivity,ACE genotype, angiotensinogen, renin,
HbA1c, duration of diabetes, bodymass index and AT1R
and AT2R genotype were included. A p value of less than
0.05 (two-sided) was considered significant.
Results
The clinical characteristics of the cohort are shown in
Table 1. We were able to obtain most, but not all data for all
the patients. A few are missing, for example the presence or
Table 1 Complications and medication of the total group of
patients
Complication/medication Number of patients (n) Percentage (%)
Retinopathy
No 126 45.0
Simplex 107 38.2
Laser-treated 47 16.8
Nephropathy
No 194 72.1
Microalbuminuria 50 18.6
Proteinuria 20 7.4
High serum creatinine 5 1.9
Senso-motor neuropathy
No 184 65.5
Asymptomatic 64 22.8
Symptomatic 33 11.7
Autonomic neuropathy
No 151 83.4
Symptomatic 30 16.6
Stroke
No/yes 281/5 98.3/1.7
Myocardial infarction/angina
No/yes 271/15 94.8/5.2
Amputation
No/yes 282/4 98.6/1.4
Hypertension
No/yes 230/55 80.7/19.3
Medication
ACE-inhibitors no/yes 227/60 79.1/20.9
ARB no/yes 276/11 96.2/3.8
CaCB no/yes 255/14 94.8/5.2
BB no/yes 281/6 97.9/2.1
Diuretics no/yes 259/28 90.2/9.8
ARB Angiotensin II-receptor blocker, CaCB Calcium channel
blocker, BB Beta-blocker
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absence of autonomic neuropathy, which was investigated
in only about two thirds of patients. Plasma SSAO activity
in the total group of diabetic patients was two-fold higher
than in normal control subjects (693±196 vs 352±102mU/l;
p<0.001) [21]. In the group with late complications, plasma
SSAO activity was higher than in the group without late
complications (727±202 vs 627±164 mU/l, p<0.001). Pa-
tients with hypertension had higher plasma SSAO activity
than normotensive patients (782±236 vs 671±180 mU/l,
p<0.001), and the 60 patients treated with ACEI had higher
plasma SSAO activity than those not on ACEI (786±218 vs
668±183 mU/l, p<0.0001).
Univariate regression analysis of the data of all patients
showed plasma SSAO activity to be positively correlated
with serum ACE activity (Table 2). After exclusion of
patients on ACEI and angiotensin receptor blocker (ARB)
therapy, the correlation persisted (r=0.27, p<0.001; Fig. 1a).
Positive correlations were also found with duration of
diabetes, HbA1c and renin, while negative correlations were
found with body mass index and angiotensinogen. No
correlationswithAT1R andAT2R genotypeswere found.No
overall correlation was found between plasma SSAO ac-
tivity and ACE genotype (p=0.172; Table 3). In a bivariate
regression analysis including all patients not treated with
ACEI or ARB, serum ACE activity and ACE genotype
were both predictors for plasma SSAO activity (r=0.39, p<
0.001), with standardised beta coefficients of respectively
0.47 and −0.35 (Table 4). Thus, within the three separate
genotypes a stronger correlation was found between plasma
SSAO and serum ACE activities (Fig. 1b, Table 3) than in
the overall regression analysis disregarding genotype.
In a backward stepwise multiple regression model in-
cluding patients not treated with ACEI or ARB and entering
11 relevant parameters (serumACE activity,ACE genotype,
angiotensinogen, renin, HbA1c, duration of diabetes, hyper-
tension, late complications, body mass index and AT1R and
AT2R genotypes), the subsequent removal of non-signifi-
Table 2 Correlations of semicarbazide-sensitive amine oxidase in
univariate analyses
Parameter r value p value
ACE activity 0.246 0.001
Duration of diabetes 0.175 0.003
HbA1c 0.161 0.007
Body mass index −0.141 0.020
Angiotensinogen −0.187 0.002
Renin 0.138 0.020
Fig. 1 Correlation between plasma semicarbazide-sensitive amine
oxidase (SSAO) and serum ACE activities in all patients not on an-
giotensin-converting enzyme inhibitor or angiotensin receptor block-
er treatment (a) and in the same patients, grouped according to ACE
I/D polymorphism (b). Key (b): crosses, II; squares, ID; circles, DD
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cant variables resulted in serum ACE activity (p<0.0001),
ACE genotype (p<0.0001), and HbA1c (p=0.022) as the
main predictors for plasmaSSAOactivity (r=0.42,p<0.001)
(Table 4). Excluding ACE activity and genotype, a similar
multiple regression analysis resulted in HbA1c (p=0.008),
late complications (p=0.023) and body mass index (p=
0.035) as the best predictors. However, this was at a far less
significant level (r=0.29, p=0.001) (Table 4).
Discussion
Although plasma SSAO is elevated in diabetes, the reg-
ulation of SSAO formation remains obscure. Our study
showed a highly significant positive correlation between
plasma SSAO and serum ACE activity. In fact, serum ACE
activity was the most significant predictor of SSAO level in
a multivariate analysis.
In contrast to the lack of knowledge of factors control-
ling SSAO, it is known that 30–40% of the variation in
serum ACE activity in Caucasians is associated with the
I(nsertion)/D(eletion) polymorphism of the ACE gene [14,
20]. Thus D allele carriers have higher ACE activity than
I allele carriers [18, 20]. The exact significance of ACE
activity level or genotype for the general renin–angiotensin
system activity is not certain and angiotensin II concentra-
tions are not influenced by ACE genotypes [14]. However,
the ACE I/D genotype has been shown to determine bra-
dykinin metabolism [25, 26]. And while the DD genotype
has been associated with increased occurrence of cardio-
vascular complications in some studies, just as often such
an association could not be found [27].
The overall positive correlation between plasma SSAO
activity and serum ACE activity suggests that a common
factor is involved in the regulation and expression of ACE
and SSAO. The fact that there was no overall difference in
plasma SSAO between the ACE genotypes implies that the
ACE gene is not the factor in question. This is supported
by the stronger positive correlation between ACE and
SSAO activities and by the negative correlation between
the ACE genotype and SSAO in the multivariate analysis.
This indicates that at a fixed ACE activity, SSAO as well
as ACE activity receive a greater contribution from the
unknown factor in the II genotype than in the ID and DD
genotypes.
Both SSAO and ACE are ectoenzymes occurring in a
membrane-bound and a soluble form. The relation between
soluble and membrane-bound human SSAO is not firmly
established, but experiments with transgenic mice and rats
strongly suggest that the major source of soluble SSAO is
membrane-bound SSAO from endothelial cells and adipo-
cytes [8, 9]. Thus, it seems likely that the soluble form is
formed frommembrane-bound SSAO by shedding, as is the
case forACE [7, 28]. The correlation between plasmaSSAO
and serum ACE activities might therefore be explained by a
common sheddase or secretase. A common regulatory factor
in the production of the two enzymes might also be an ex-
planation. In a recent study, however, Göktürk et al. [29]
found a negative correlation between plasma SSAO and
mRNA in transgenic mice with alloxan-induced diabetes
and concluded that the increase in plasma SSAO in diabetes
must be explained by post-transcriptional changes and not
by an elevated transcription rate. A third possibility is the
existence of two independent mechanisms, both driven by
the pathophysiology of diabetes or its complications. In this
respect the suggestion of Göktürk et al. [29] that the ex-
cess flux of glucose in diabetes may enhance glycosylation,
which, by protecting proteins from degradation, may in-
crease the life-span of SSAO, would be interesting, if such a
mechanism operated for SSAO and ACE.
The positive correlation between serum ACE activity
and plasma SSAO activity can also explain the higher
SSAO levels in patients on ACEI therapy, which at first
sight seems contradictory. However, treatment with enzyme
inhibitors often leads to an increase in production of the
enzymes, in an attempt to restore the pre-treatment condi-
tion. SerumACE activity is a direct reflection of the amount
of ACE protein under normal circumstances, but during
ACEI treatment the protein is prevented from expressing its
enzyme activity, resulting in low activity, but with the
protein still present, and in fact, it has been shown that
production of the ACE protein increases [30]. Thus, the
higher plasma SSAO activity in subjects on ACEI therapy
is in line with such elevated serum concentrations of ACE
protein.
Table 3 Semicarbazide-sensitive amine oxidase (SSAO) and ACE
activities and their correlations according to ACE I/D genotype
ACE genotype Number
(n)
SSAO
(mU/l)
ACE
(U/l)
r value p value
II 52 677±174 33±8 0.388 0.005
ID 122 681±186 47±13 0.332 0.001
DD 51 627±181 61±19 0.501 0.001
Table 4 Correlations of semicarbazide-sensitive amine oxidase in
multiple regression analyses
Model Parameter Standardised beta r value p value
A ACE genotype −0.35 <0.0001
Serum ACE activity 0.47 <0.0001
Overall 0.39 <0.0001
B ACE genotype −0.34 <0.0001
Serum ACE activity 0.44 <0.0001
HbA1c 0.14 0.022
Overall 0.42 <0.0001
C HbA1c 0.19 0.008
Late complications 0.16 0.023
Body mass index −0.15 0.035
Overall 0.29 <0.0001
Model A: bivariate model with serum ACE activity and ACE
genotype. Model B: backward stepwise analysis including serum
ACE activity, ACE genotype, renin, HbA1c, angiotensinogen,
duration of diabetes, hypertension, late complications, body mass
index and AT1R and AT2R genotypes. Model C: like model B but
excluding serum ACE activity and ACE genotype
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As expected, plasma SSAO activity was strongly ele-
vated in the total group of patients compared to non-diabetic
controls. This elevation may be driven by hyperglycaemia,
as we found a positive correlation between plasma SSAO
activity and HbA1c in accordance with previous studies
[10–13]. Importantly, HbA1c was the only predictor besides
ACE activity and genotype in the full multiple regression
analysis. This robust association is intriguing, as SSAO has
been implicated in the glycation process, as suggested by
the inhibitory effect of aminoguanidine (an SSAO inhibitor)
on glycation and AGE formation [31].
Plasma SSAO was higher in patients with late complica-
tions than in those without, in agreement with earlier reports
[10–13], as well as in patients with hypertension or on
ACEI treatment, two groups which overlap to a large ex-
tent. However, when including serum ACE activity in the
backward multiple regression model, late complications,
hypertension, and ACEI treatment were removed from the
model, indicating that these factors are not independently
associated with plasma SSAO activity. This is in accor-
dance with an earlier report that hypertension by itself is not
associated with elevated plasma SSAO activity [1].
A negative correlation was found between body mass
index and plasma SSAO, as we have reported previously in
a mixed group of type 1 and type 2 diabetic patients [11].
The correlation remained significant in the multiple regres-
sion model without ACE activity, but disappeared in the full
model. Previous papers have reported either no correlation
in type 2 [12] or even a positive correlation, also in a mixed
group of type 1 and type 2 patients [13]. Both sample size
and differences between the two types of diabetes might
play a role in this discrepancy.
In conclusion, we have demonstrated a strong positive
correlation between plasma SSAO and serum ACE activ-
ity in type 1 diabetes suggesting that both enzymes are
regulated by a common factor which is not the ACE gene.
We have shown that plasma SSAO is positively associated
with level of glycaemic control, and confirmed that plas-
ma SSAO activity is elevated, the more so in the presence
of late complications, hypertension and ACEI therapy. The
increasing evidence for SSAO having both deleterious
effects in terms of cytotoxicity, AGE-formation, and oxi-
dative stress [1, 3–5], and beneficial effects in terms of
enhanced glucose uptake, proper formation of blood ves-
sel walls, and anti-inflammatory functions [2, 6, 9] sug-
gests the importance of regulatory factors to keep SSAO
activity within narrow limits. The elevation of SSAO in
diabetes could thereby be an adverse as well as a beneficial
factor. It is therefore important to investigate whether the
selective SSAO inhibitors currently being developed have
similar and additional beneficial effects on the progress of
diabetic complications as has been established for ACEI.
Furthermore, identification of the factor(s) upregulating
both SSAO and ACE in diabetes may provide a new target
for drugs in the prevention of diabetic complications.
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